Fulcrum Therapeutics (FULC) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Surrozen (SRZN) has outperformed Fulcrum Therapeutics (FULC) over the past year, gaining 82.9% versus a loss of 60.3%. Over five years, SRZN leads with a -73.5% price change compared with -85.9% for FULC. Surrozen is the larger company by market cap ($328.7 million vs $286.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FULC | SRZN |
|---|---|---|
| Share price | $3.75 | $27.97 |
| Market cap | $286.11M | $328.75M |
| 1-day change | +2.18% | +11.23% |
| YTD return | -67.55% | +11.26% |
| 1-year return | -60.28% | +82.87% |
| 5-year return | -85.88% | -73.48% |
| EPS (TTM) | $-1.21 | $-39.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.74 | $37.83 |
| 52-week low | $2.83 | $11.39 |
| Distance from 52-week high | -76.18% | -26.06% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | -2.13% | +73.04% |
| Average volume | 1.53M | 475.02K |
| Shares outstanding | 76.30M | 11.75M |
| Employees | 9 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed FULC by 143.2 percentage points over the past year.
About Fulcrum Therapeutics
FULC stock →Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
FULC vs SRZN FAQ
Which is bigger, Fulcrum Therapeutics or Surrozen?
Surrozen (SRZN) is larger, with a market capitalization of $328.75M compared with $286.11M for Fulcrum Therapeutics (FULC).
Which stock has performed better over the past year, FULC or SRZN?
SRZN returned +82.87% over the past 12 months, compared with -60.28% for FULC (price return, excluding dividends). Past performance does not predict future results.
Are Fulcrum Therapeutics and Surrozen in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Fulcrum Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Surrozen.